Method for the normalization of sexual response and amelioration of long term genital tissue degradation

a technology of genital tissue degradation and normalization method, applied in the direction of biocide, plant growth regulator, animal husbandry, etc., can solve the problems of inappropriate timing of sexual response between sexual partners, frequent mismatch of response timing, inappropriate timing of sexual response, etc., to normalize the timing of sexual response and increase genital vasodilation

Inactive Publication Date: 2006-12-14
HEATON JEREMY P W +1
View PDF0 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012] It has been found, in accordance with one embodiment of the present invention that the acute administration of an agent which acts upon mid-brain dopaminergic, serotonergic, oxytocinergic or nitroxidergic pathways to initiate ...

Problems solved by technology

Timing of the various aspects or parameters of sexual response between partners engaging in sex is important and often mis-matched due to psychological, or sometimes biogenic, dysfunction in one or both of the partners.
Even in sex partners having sexual responses deemed to fall within the norm, there is a frequent mis-match of the timing of response.
Most women are unable to reach orgasm within this short period of time, one cause ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for the normalization of sexual response and amelioration of long term genital tissue degradation
  • Method for the normalization of sexual response and amelioration of long term genital tissue degradation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] In the first embodiment of the invention, a central nervous system sexual response initiator is administered to a mammal in an acute dose to one or both partners in the period just prior to sexual intercourse, preferably in a dose insufficient to cause effective vasocongestive arousal, but sufficient to increase genital vasodilation to aid in the normalization of the timing of sexual response between the sexual partners. The drug is administered during the period between about two to about one-hundred-twenty minutes prior to sexual relations, preferably in the period between about two and sixty minutes prior to sexual relations.

[0015] In the case where the male suffers from the sexual dysfunction termed sexual arousal disorder (inability to attain the psychic readiness, and / or sustain an erection satisfactory for normal coitus) or the condition known as premature ejaculation, the drug is administered to the male partner. Where the female suffers sexual arousal disorder (pers...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The method is applicable not only to adjusting or normalizing the timing of sexual response in humans, but in the breeding of valuable commercial animals such as horses, cattle, sheep, swine and the like and domesticated pets such as dogs and cats. In an alternative embodiment, the present invention provides a method for the prophylactic treatment of long-term tissue degradation in the genital organs comprising the administration to a mammal of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective vasocongestive arousal. The preferred central nervous system sexual response initiator is apomorphine or a pharmaceutically acceptable acid addition salt thereof.

Description

TECHNICAL FIELD [0001] The present application relates to pharmaceutical formulations and to medical methods of treatment. More particularly, the present invention concerns the use of a compound which acts as a central nervous system sexual response initiator for the normalization of the timing of sexual response in humans and for the prophylaxis or treatment of long-term damage to genital organ. BACKGROUND OF THE INVENTION [0002] Proper sexual functioning in men and women depends upon a combination of steps including 1) establishment of the appropriate anticipatory mental set (“desire”), 2) effective vasocongestive arousal (an erection in the male sufficient for vaginal penetration and, in the female, clitoral erection, vaginal engorgement and lubrication), and 3) orgasm. The timing of these steps between partners engaging in sexual relations is mediated by one or more of several compounds which act in neurological pathways in the mesencephalon or mid-brain. These pathways include ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/506A61K31/498A61K31/48A61K31/137A61K31/405A61K31/00A61K31/473
CPCA61K31/00A61K31/137A61K31/405A61K31/506A61K31/48A61K31/498A61K31/473A61P15/00
Inventor HEATON, JEREMY P. W.ADAMS, MICHAEL A.
Owner HEATON JEREMY P W
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products